Rebutting Defense IME Opinions on Medication Overuse

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 26, 2026 | 9 min read

Defense IME physicians frequently opine that PI plaintiffs are over-medicated or that prescribed medications are unrelated to the accident. Cross-examining these opinions requires specific pharmaceutical knowledge — understanding the clinical basis for each medication and the flaws in the IME methodology.

Rebutting Defense IME Opinions on Medication Overuse

Defense independent medical examination (IME) physicians routinely opine that personal injury plaintiffs are taking too many medications, that certain prescriptions are unrelated to the accident, or that cheaper alternatives should have been prescribed. These opinions are among the most damaging threats to pharmacy lien recovery at trial — a credible-sounding medical expert telling the jury that medications were unnecessary directly undermines the damages claim. Effective cross-examination of these opinions requires pharmaceutical-specific preparation that most PI attorneys do not undertake without pharmacist guidance.

• Defense IME opinions on medication overuse typically rely on three predictable arguments: pre-existing condition attribution, duration challenges, and generic substitution
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages — this documentation provides the clinical ammunition for cross-examination of IME medication opinions
• As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, most defense IME physicians are not pharmacists and lack specialized pharmacological training in medication mechanism analysis
• The most effective cross-examination strategy exposes the IME physician's limited pharmaceutical knowledge rather than challenging their medical credentials directly
• Every medication the defense IME challenges should have a prepared MERIT-referenced rebuttal with specific pharmacological detail

The Three Standard IME Medication Attacks

Attack 1: "These Medications Were for Pre-Existing Conditions"

The IME physician reviews medical records showing pre-existing diagnoses — degenerative disc disease, prior back pain, anxiety history — and attributes some or all medications to those pre-existing conditions rather than the accident.

The flaw: This opinion typically ignores the temporal relationship between the accident and the prescription. A patient with pre-existing degenerative disc disease at L4-L5 who develops new radiculopathy symptoms after a rear-end collision — confirmed by post-accident MRI showing a new disc herniation — has an accident-related condition that requires medication, regardless of the pre-existing degeneration.

Cross-examination approach:

• "Doctor, you noted that the patient had pre-existing degenerative disc disease. Is it correct that degenerative disc disease is a condition present in a significant percentage of asymptomatic adults?"
• "The patient was prescribed gabapentin seven days after the accident. Were they taking gabapentin before the accident?"
• "If the patient was not taking this medication before the accident, and the prescribing physician documented radiculopathy symptoms that began after the accident, what is the medical basis for attributing this prescription to a pre-existing condition?"

Attack 2: "The Patient Was on Too Many Medications"

The IME physician counts the number of medications and opines that the regimen is excessive — implying over-treatment or billing maximization.

The flaw: This opinion treats medication count as a proxy for appropriateness, which is pharmacologically unsound. Multi-system injuries require multi-mechanism treatment. A patient with cervical radiculopathy, thoracic muscle spasm, post-traumatic migraine, NSAID-induced GI risk, and accident-related sleep disruption appropriately takes five or more medications — each addressing a different physiological system through a different pharmacological mechanism.

Cross-examination approach:

• "Doctor, how many distinct injury components did the treating physician document?"
• "Is there a single medication that treats nerve pain, muscle spasm, migraine, and sleep disruption simultaneously?"
• "If no single medication addresses all of these conditions, isn't it medically appropriate to prescribe separate medications for each condition?"

[!KEY] The most effective cross-examination of the "too many medications" opinion forces the IME physician to identify which specific medication they would eliminate and explain what clinical consequence the patient would experience without it. Most IME physicians cannot answer this question convincingly because each medication addresses a documented clinical need.

Attack 3: "Generic Alternatives Were Available"

The IME physician opines that brand-name medications should have been prescribed as generics, implying that brand selection was economically rather than clinically motivated.

The flaw: This opinion assumes that brand and generic medications are always interchangeable. For many PI medications, they are not. Qulipta (atogepant) is a CGRP receptor antagonist with no generic equivalent and no generic drug in the same mechanism class. Journavx (suzetrigine) is a Nav1.8 inhibitor with no pharmacological equivalent of any kind. These are not brand-versus-generic choices — they are distinct medications.

Cross-examination approach:

• "Doctor, you recommended generic topiramate instead of Qulipta. Are these the same drug class?"
• "Qulipta is a CGRP receptor antagonist. Topiramate is an anticonvulsant. Do they work through the same mechanism?"
• "If they work through different mechanisms, how are they clinically interchangeable?"

Using the MERIT Report for Cross-Examination Preparation

The MERIT report from LienScripts provides the pharmaceutical detail needed to prepare effective cross-examination. For each medication on the lien, the MERIT report includes:

• Clinical indication — what the medication treats and why it was prescribed
• Mechanism of action — how the drug works pharmacologically
• Causation link — the documented accident injury that the medication addresses
• Therapeutic rationale — why this specific medication was selected over alternatives

Use each MERIT entry to prepare medication-specific cross-examination questions. When the IME physician challenges gabapentin, you have the MERIT-documented rationale for gabapentin's role in treating the patient's documented radiculopathy. When the IME physician challenges a brand medication, you have the MERIT explanation of why that medication's mechanism is distinct from generic alternatives.

[!TIP] Provide your MERIT report to your pharmacist expert witness (if retained) and ask them to prepare a medication-by-medication rebuttal to the IME physician's opinions. This creates a direct evidentiary confrontation: the defense IME physician's generalized opinions versus the plaintiff pharmacist's specific, documented clinical analysis.

Exposing IME Methodology Limitations

Defense IME physicians typically conduct a single examination — often lasting 15-30 minutes — and review selected medical records. Their medication opinions are based on this limited contact and chart review.

Contrast this with the treatment reality: the prescribing physician saw the patient repeatedly over months, monitored medication response, adjusted dosages, and made prescribing decisions based on ongoing clinical assessment.

Cross-examination questions:

• "Doctor, how many times did you examine this patient?" (Once)
• "How long was your examination?" (15-30 minutes)
• "The treating physician saw this patient [X] times over [Y] months. Did you review all of those visit notes?"
• "Did you perform any of the clinical assessments that led to the prescribing decisions you are now challenging?"

Preparing Your Treating Physician

The treating physician's testimony is your primary defense against IME medication opinions. Prepare the treating physician to:

1. Explain the clinical basis for each prescription
2. Describe the clinical assessments performed at each prescribing decision point
3. Address why the specific medications were selected over alternatives
4. Explain the treatment progression and why medications were continued, adjusted, or added

The MERIT report can serve as a reference document for the treating physician's preparation — it provides a concise summary of the pharmacological rationale for each medication that the physician can review before testimony.

[!KEY] The combination of treating physician testimony (clinical decision-making), pharmacist expert testimony (pharmacological rationale), and MERIT documentation (written clinical analysis) creates a three-layer defense against IME medication challenges that is extremely difficult for the defense to overcome.

Frequently Asked Questions

Contact LienScripts to discuss MERIT report preparation and pharmacist expert support for IME rebuttal.

Related Resources

• Using Pharmacist Expert Witnesses in PI Cases
• Top Adjuster Attacks on Pharmacy Liens — And How to Rebut Them
• What Is a MERIT Report?
• Myth: Multiple Prescriptions Mean Over-Treatment